SMBC, Shinsei Bank, Mitsubishi UFJ and Kyoto Chuo Shinkin all backed cancer therapy developer Chordia Therapeutics’ latest round, which follows a Takeda-backed series A.

Japan-based oncology drug developer Chordia Therapeutics has secured $27m in a series B round featuring financial services firms Sumitomo Mitsui Banking Corporation (SMBC), Shinsei Bank, Mitsubishi UFJ and Kyoto Chuo Shinkin Bank.

The round was co-led by investment firm Jafco and university venture capital fund Innovation Kyoto 2016 (Kyoto iCap 1st Fund), and included VC firm Nippon Venture Capital.

The banks invested through VC subsidiaries SMBC Venture Capital, Shinsei Capital Partners, Mitsubishi UFJ Capital and Chushin Venture Capital respectively.

Founded…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?